Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have received a consensus rating of "Buy" from the fifteen research firms that are covering the stock, MarketBeat reports. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $172.14.

A number of equities research analysts have recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Axsome Therapeutics in a report on Monday, April 7th. They issued a "buy" rating and a $200.00 target price on the stock. Mizuho increased their target price on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research report on Thursday, March 27th. HC Wainwright reduced their price target on shares of Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Bank of America raised their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC restated a "buy" rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, April 1st.

Axsome Therapeutics Price Performance

Shares of AXSM stock opened at $108.30 on Tuesday. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13. The firm has a market capitalization of $5.33 billion, a price-to-earnings ratio of -18.08 and a beta of 0.46. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm has a fifty day moving average of $110.27 and a 200-day moving average of $105.43.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. On average, equities research analysts forecast that Axsome Therapeutics will post -2.79 earnings per share for the current year.

Institutional Trading of Axsome Therapeutics

A number of institutional investors have recently modified their holdings of AXSM. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Axsome Therapeutics during the 1st quarter valued at approximately $25,000. NBC Securities Inc. bought a new stake in Axsome Therapeutics during the 1st quarter worth approximately $31,000. Quantbot Technologies LP bought a new stake in Axsome Therapeutics during the 1st quarter worth approximately $31,000. AlphaQuest LLC bought a new stake in Axsome Therapeutics during the 1st quarter worth approximately $38,000. Finally, Neo Ivy Capital Management bought a new stake in Axsome Therapeutics during the 1st quarter worth approximately $41,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.